Transfection of plasmid vectors coexpressing short hairpin RNA (shRNA) for focal adhesion kinase (FAK) and epidermal growth factor receptor (EGFR) significantly inhibited protein level of FAK and EGFR. Knockdown of FAK and EGFR expression significantly inhibited cell proliferation and induced cell apoptosis of A549 lung cancer cells in vitro. In A549 subcutaneous xenograft model, mice treated for 3 weeks with plasmid that coexpresses FAK and EGFR shRNA had significantly smaller tumors than those in control mice (Po0.01). FAK and EGFR dual silencing also significantly decreased microvessel density, tumor cell proliferation and increased the level of apoptosis in tumor cells. Moreover, administration with plasmid that coexpresses FAK and EGFR shRNA significantly inhibited the A549 experimental lung metastases. Collectively, our data suggest that the dual inhibition of FAK and EGFR by using plasmid vector-based RNA interference might be a novel therapeutic approach to the treatment of human NSCLC.
INTRODUCTION
Lung cancer has emerged as a leading cause of cancer-related mortality in the world. 1, 2 Lung cancers are divided into small-cell lung cancer (SCLC) and non-small-cell lung cancer (NSCLC) based on their histology and cellular origin. It has been reported that NSCLC constitutes about 80-85% of all lung cancers and is the most common cause of death in men and second only to breast cancer in woman. 3 The majority of NSCLC patients are diagnosed with late-stage disease and most of those diagnosed with earlystage disease will develop recurrence, experiencing metastatic disease. 4 The median survival of a patient with advanced or metastasis NSCLC is approximately 6-8 months and chemotherapy provides only minimal gains in overall survival, resulting in a dismal 5-year survival rate of o15%.
2 Current therapies are ineffective, thus new approaches are needed to improve the therapeutic ratio.
Metastasis is a multistep process in which primary tumor cells are re-established at distant organ sites and develop into secondary tumors. It accounts for the majority of death among patients with solid tumors. 5 The process of metastasis requires a disseminating cancer cell to survive an environment that actively promotes apoptosis. Thus, for a cancer cell to metastasize effectively, it must possess survival signals that suppress apoptosis. One survival signal that has been shown to modulate apoptotic signaling is focal adhesion kinase (FAK). 6 FAK, a nonreceptor protein tyrosine kinase, localizes to regions of the cell that attach to the extracellular matrix, the focal adhesions. FAK activity is regulated by extracellular matrix receptors and integrins, and implicated in several cellular processes, such as proliferation, apoptosis, motility and invasion. 7 FAK is overexpressed and/or constitutively activated in various malignant tumors, including tumors derived from breast, ovary, head and neck. [8] [9] [10] It has also been reported that FAK was overexpressed in NSCLC tissues compared with its surrounding non-neoplastic tissue. 11 Moreover, recent report has demonstrated that downregulation of FAK using small interfering RNA (siRNA) stimulates the apoptosis of cultured NSCLC A549 cells. 12 The epidermal growth factor receptor (EGFR) is a member of a family of growth factor receptor tyrosine kinases, which includes EGFR (ErbB-1), HER2/neu (ErbB-2), HER3 (ErbB-3) and HER4 (ErbB-4). 13 Among the four kinds of subtype, EGFR is expressed in a majority of NSCLC. 14, 15 It has been a promising target for the development of therapeutic agents. However, clinical trial findings and research have revealed that targeted EGFR monotherapy confronts the complexity of alternative survival pathways, which may overcome targeted inhibition in cancer cells. 16 Recent reports have suggested that FAK serves to integrate EGFR signals upon EGF induction, promoting tumor cell motility and invasion. 17, 18 Loss of FAK from the focal adhesions can inhibit EGFR signaling at the cell membrane and transmit a proapoptotic signal. 19 Moreover, inhibition of both FAK and EGFR signaling pathways cooperatively induces death receptor-mediated apoptosis in cultured human breast tumor cells. 20 Based on these observations, we therefore hypothesized that the dual inhibition of FAK and EGFR signaling pathways might be more beneficial in the treatment of NSCLC.
RNA interference (RNAi) is a specific way of post-transcriptional gene silencing by a specific double-stranded RNA molecules, which is homologous to the sequence of the target gene. RNAi technology is now widely used as a potential therapeutic strategy because of its high efficacy and specificity in downregulating gene expression. 21 Compared with chemically or enzymatically 1 synthesized small siRNA, plasmid vector-mediated shRNA expression system is less expensive, more easy and efficient in suppressing the expression of targeted genes, further expanding the utility of RNAi. 22 In this study, we developed a bicistronic plasmid vector-expressing shRNA directed against both FAK and EGFR under the control of a human U6 promoter. We show that RNAi driven by these shRNA-based plasmid constructs can effectively silence FAK and EGFR gene expression at the protein level. Functional analyses revealed that the abrogation of both FAK and EGFR expression strongly inhibited proliferation and induced apoptotic cell death in vitro. Furthermore, administrating with these shRNA-based plasmids encapsulated by 1,2-bis(oleoyloxy)-(trimethylammonio) propane-cholesterol (DOTAPchol) cationic liposome via tail vein significantly inhibited the growth of established subcutaneous A549 xenografts and experimental lung metastasis.
MATERIALS AND METHODS

Vector construction
The pGensil-2/U6 parental vector (Genesil Biotechnology Company, Wuhan, China) was used for DNA vector-based RNAi synthesis. Small interfering oligonucleotide specific for FAK (5 0 -GATCCGCCACCTGGGCCAG TATTATTTCAAGACGATAATACTGGCCCAGGTGGTTTTTTGAATTCA-3 0 ) and for EGFR (5 0 -GATCCGCACAGTGGAGCGAATTCCTTTCAAGACGAGGAATTCGCTC CACTGTGTTTTTTGTCGACA-3 0 ) were synthesized and annealed. 23, 24 An FAK-EGFR RNAi plasmid vector that expresses shRNA for both FAK and EGFR under the control of a human U6 promoter was constructed by inserting pairs of the annealed DNA oligonucleotide specific for FAK at the HindIII site and EGFR at BamHI site sequentially into the pGensil-2/U6 vector (p-shFE). Also, shRNA expression vectors for FAK (p-shFAK) and EGFR (p-shEGFR) singly were constructed. Oligonucleotide sequences of HK-shRNA, which have no homology with any of the mammalian sequence, were designed as negative control (p-shHK). All of the constructs were verified by DNA sequencing. Plasmids were extracted using EndoFree Plasmid Giga kits (Qiagen GmbH, Hilden, Germany) from DH5a Escherichia coli transformants and stored at À 20 1C before use. The concentration was determined by measuring A 260 /A 280 ratio using ultraviolet spectrophotometry.
Cell culture and transfection
The human lung adenocarcinoma cell line, A549 cell line, was obtained from American Type Culture Collection (ATCC, Manassas, VA, USA). Cells were cultured in RPMI-1640 medium supplemented with 10% heatinactivated fetal bovine serum, 20 mM L-glutamine, 100 U ml À 1 of penicillin G sodium and 100 mg ml À 1 of streptomycin. Cells were maintained in a humidified atmosphere containing 5% CO 2 at 37 1C. Cell transfection was carried out using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's construction. At 72 h after transfection, cells were used for cell proliferation assays, immunoblot analysis, flow cytometry analysis and Hoechst 33258 staining.
Cell proliferation assay
Viability of cells 72 h after transfection was evaluated using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay (Sigma, St Louis, MO, USA). MTT was added to the culture medium in each well of a 96-well plate at a concentration of 500 mg ml À 1 , and the plates were incubated for 4 h at 37 1C. Acidic isopropyl alcohol (0.04 N HCl/isopropyl alcohol) was immediately added to all wells and mixed vigorously so that the dark blue crystals dissolved effectively. Absorbance was measured at 570 nm.
Western blot A549 cells were harvested and rinsed twice with phosphate-buffered saline (PBS) 72 h after transfection. Cell extracts were prepared with RIPA lysis buffer (50 mM Tris, 150 mM NaCl, 1% Triton, 0.5% deoxycholate, 2 mM ethylenediaminetetraacetic acid) supplemented with 100 Â cocktail (Sigma) and cleared by centrifugation at 12 000 g at 4 1C for 30 min. Total protein concentration was measured with the BCA assay. Cell extracts that contained equal total protein were subjected to 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis, and the resolved proteins were transferred to polyvinylidenefluoride membranes (Invitrogen). After being blocked with 0.5% non-fat milk for 1 h at room temperature, membranes were incubated with mouse anti-FAK (1:200 dilution; Santa Cruz Biotechnology, Santa Cruz, CA, USA) or mouse anti-EGFR (1:1000 dilution; Cell Signaling Technology, Beverly, MA, USA) antibody in TBS/T (Tris-buffered saline and Tween-20) overnight at 4 1C. The blots were labeled with horseradish peroxidase-conjugated anti-mouse secondary antibody, and visualized with enhanced chemiluminescence detection system (Pierce Biotech, Rockford, IL, USA). Equal loading was normalized by glyceraldehyde 3-phosphate dehydrogenase.
Assessment of apoptosis in vitro
Cell apoptosis was analyzed by Hoechst 33258 staining (Apoptosis-Hoechst Staining Kit; Beyotime Biotechnology, Haimen, China) 72 h after transfection. Briefly, cells were immersed in 0.5 ml of methanol for 15 min, followed by rinsing twice with PBS. Then, cells were stained with 1 mg ml À 1 Hoechst 33258 compounds in a dark chamber at room temperature for 10 min and again rinsed twice with PBS. Cells were analyzed by fluorescence microscopy using excitation and emission wavelengths of 350 and 460 nm, respectively. The apoptotic cells are featured as pyknotic and fragmented nuclei emitting intense fluorescence.
Quantitative evaluation of cellular apoptosis was performed by flowcytometric analysis. Briefly, both of the floated cells and the attached cells were collected 72 h after transfection and washed twice with cold PBS. Cells were stained with 50 mg ml À 1 propidium iodide plus 0.1% Triton X-100, and collected on a flow cytometer (Becton Dickinson, San Jose, CA, USA). Data were analyzed using the BD FACSDiva software (BD Biosciences, Franklin Lakes, NJ, USA).
Cationic liposome and preparation of plasmid/lipoplexes
Cationic liposome was prepared as multilamellar vesicles for in vivo use as described previously. 25 Briefly, DOTAP from Avanti Polar Lipids (Alabaster, Shelby County, AL, USA) and cholesterol (Sigma) were mixed in a 1:1 molar ratio, dried down in round-bottomed tubes, and then rehydrated in 5% glucose solution by heating at 50 1C for 6 h. For in vivo injection, plasmid/ lipoplexes were prepared immediately before injection by gently mixing cationic lipids with plasmid DNA at a ratio of 25 mg total cationic liposome to 5 mg plasmid DNA, to a final concentration of 25 mg plasmid DNA per ml in a sterile solution of 5% glucose in water.
In vivo transfection efficiency in subcutaneous tumors
To determine the transfection efficiency of the complexes in NSCLC in vivo, nude mice were injected with A549 tumor cells (2 Â 10 6 /100 ml) subcutaneously on the right flank. When the tumors reached 200-300 mm 2 in size, a single dose of DOTAP-chol/DNA complex (5 mg of p-EGFP (enhanced green florescent protein)-N1; BD Biosciences Clontech, Palo Alto, CA, USA) was injected intravenously. At 48 h after injection, mice were euthanized and tumors were removed, frozen in OCT compound and sectioned on a freezing microtome (Leica, Glattbrugg, Switzerland) at 10 mm. Green fluorescence was visualized and photographed directly under a fluorescence microscope.
Tumor growth and treatments in vivo
In A549 xenograft model, 2 Â 10 6 A549 cells were injected subcutaneously into the right flank regions of athymic nude (nu/nu) mice (6-8 weeks). After a week, when the tumors could be palpable, the animals were randomly assigned to five independent groups of five mice and subjected to systemic treatment with one of the following treatments: 5% glucose, p-shHK/lipoplexes, p-shFAK/lipoplexes, p-shEGFR/lipoplexes and p-shFE/ lipoplexes. Plasmids and DOTAP-chol complex in 200 ml of 5% glucose were injected into the mouse tail vein three times a week (on Monday, Wednesday and Friday). Tumor diameters were measured once every 3 days during the treatment period. Tumor volume was estimated using the formula: tumor volume (mm 3 ) ¼ length (mm) Â (width (mm)) 2 Â 1/2. The weight, appetite and behavior of the mice were observed. Mice were euthanized after 12 times of treatment and dissected tumors were weighed. The tumors and viscera were examined grossly and microscopically stained with hematoxylin and eosin (H&E).
An experimental A549 lung metastasis model was used to study the effects of FAK-EGFR shRNAs on the development of metastases. Briefly, athymic nude (nu/nu) mice (6-8 weeks) were inoculated with A549 cells (2 Â 10 6 ) in 200 ml PBS via tail vein injection. Pulmonary experimental metastatic tumor colonies were formed 7-10 days after inoculation. Then, Targeting FAK and EGFR for treatment of lung cancer C Li et al p-shFE/lipoplexes, p-shHK/lipoplexes or 5% glucose were administered systemically to animals by intravenous injection for three times within a week, respectively. At 2 weeks after the last injection, the animals were euthanized, and their lung tissues were excised. Tumor colonies on lung surfaces were counted under a dissecting microscope without the knowledge of the treatment groups, and the lung tissues were sectioned for further pathological and immunohistochemical analysis. Animal studies were performed in accordance with the Institutional Animal Care and Treatment Committee of Sichuan University (Chengdu, People's Republic of China).
Immunostaining
Expression of FAK, EGFR, proliferating cell nuclear antigen (PCNA) and CD31 was performed with mouse anti-human FAK antibody (Santa Cruz Biotechnology), mouse anti-human EGFR antibody (Cell Signaling Technology), mouse anti-human PCNA antibody (Santa Cruz Biotechnology) and goat anti-mouse CD31 antibody (Santa Cruz Biotechnology), respectively. Tumor sections (3-5 mm) of paraffin-embedded were mounted on 3-aminopropyltriethoxysilane (APES)-coated glass slides. Sections were deparaffinized in xylene, treated with a graded series of alcohol (100, 95 and 80% ethanol/double-distilled H 2 O (vv À 1 ), and rehydrated in PBS (pH 7.4). Antigen retrieval was carried out by heating for 5 min in a pressure cooker with 0.1 mol l À 1 citrate buffer (pH 6.0). Endogenous peroxide was blocked with 3% H 2 O 2 in methanol for 5 min. After PBS washes, slides were blocked with 5% normal goat or rabbit serum in PBS for 15 min at room temperature followed by incubation with primary mouse anti-FAK (1:100), anti-EGFR (1:50), anti-PCNA (1:100) or anti-CD31(1:100) antibody in blocking solution overnight at 4 1C. All slides were subsequently incubated with a 1: 200 dilution of biotin-conjugated goat anti-mouse or rabbit anti-goat secondary antibody for 40 min at 37 1C and streptavidin-biotin complex at 37 1C for 40 min. The immunoreaction was visualized by using diaminobenzidine peroxide solution and cellular nuclei were counterstained with hematoxylin. All specimens were evaluated using Olympus BX600 microscope and Spot Fiex camera. Control samples exposed to secondary antibody alone showed no specific staining.
To quantify mean vessel density (MVD), 10 random 0.159-mm 2 fields at Â 100 final magnification were examined for each tumor (one slide per mouse, eight slides per group) and the number of microvessels per field was counted by two investigators in a blinded manner. A single microvessel was defined as a discrete cluster or a single cell stained positive for CD31, and the presence of a lumen was required for scoring as a microvessel. To quantify proliferation index, the percentage of PCNApositive cells was counted in 10 random 0.159-mm 2 fields at Â 100 magnification.
To detect apoptotic cells in tumor tissues, terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL) assay using a DeadEnd Fluorometric TUNEL System (Promega, Madison, WI, USA) was performed following the manufacturer's protocol. Cell nuclei with dark green fluorescent staining were defined as TUNEL-positive nuclei. TUNEL-positive nuclei were monitored by fluorescence microscope. To quantify TUNELpositive cells, the number of green fluorescence-positive cells was counted in 10 random 0.011-mm 2 fields at Â 200 magnification.
Statistical analysis
Data are expressed as the mean ± s.d. Statistical analysis was performed by Student's t-test for comparing two groups and by analysis of variance for multiple group comparisons. Po0.05 was considered statistically significant. The Statistical Package for the Social Sciences (SPSS, Chicago, IL, USA) was used for all statistical analyses.
RESULTS
Effect of FAK-EGFR silencing in vitro
To examine whether the plasmid encoding FAK-EGFR shRNAs could simultaneously inhibit FAK and EGFR expression in A549 lung cancer cells by transient transfection, A549 lung cancer cells were transfected with p-shFAK, p-shEGFR, p-shFE or control p-shHK using Lipofectamine 2000. As shown in Figure 1 , analysis of the shRNA-transfected cells for FAK and EGFR expression via western blot demonstrated a specific reduction in protein levels for each gene relative to the p-shHK-transfected cells or mock cells. However, the RNAi effect was slightly more with the shRNA vector simultaneously targeting FAK and EGFR. No effects of RNAi were observed on the expression of GAPDH, which was used as an internal control for specificity and loading at protein levels. In addition, p-shHK-transfected cells also showed that RNAi-directed FAK and EGFR knockdown is specific.
Knockdown of FAK and EGFR expression inhibits cell proliferation and induces apoptosis
To access the potential effects of RNAi-mediated FAK and EGFR silencing on cell proliferation and survival, MTT analysis was performed 72 h after transfection with shRNA specific to FAK and EGFR. RNAi-targeting against FAK or EGFR had a relatively low inhibitory effect. In contrast, a dramatic reduction in proliferation was observed with RNAi simultaneously targeting FAK and EGFR (Figure 2a In vivo transfection efficiency of plasmid DNA/liposome complexes Before the in vivo treatment, we examined the biodistribution of p-shFE/lipoplexes in vivo. A plasmid encoding EGFP was used to further determine the ability of extruded DOTAP-chol liposome to effectively transfect and deliver plasmid DNA into subcutaneous A549 tumor xenografts. At 48 h following a single tail vein injection of EGFP-N1, plasmid DNA encapsulated in DOTAP-chol liposomes. Green florescence was observed in A549 tumor sections. In contrast, no green florescence was observed in control group treated with 5% glucose (Figure 3 ). And the approximate transfection efficiency in tumor xenografts was 30-40%.
Knockdown of FAK and EGFR suppresses A549 tumor growth and metastasis in vivo By having established the significant effects of FAK-EGFR knockdown by RNAi in A549 cells in vitro and determined the in vivo efficiency of DOTAP-chol delivery system, we then asked whether FAK-EGFR shRNA would also suppress the growth and metastasis of A549 tumor in nude mice. As shown in Figure 4a , although p-shFAK/lipoplexes and p-shEGFR/lipoplexes significantly inhibited the A549 tumor growth compared with control groups (Po0.05), but the degree of inhibition was less than that in p-shFE/lipoplexes-treated group (Po0.01). Tumor weight was also Immunohistochemical analysis for protein levels in tumor samples confirmed that the tumors treated with p-shFE/lipoplexes had significantly decreased FAK and EGFR levels ( Figure 4c) . Next, an experimental A549 metastatic human lung cancer model (established by intravenous injection of tumor cells) was used to explore the potential of p-shFE/lipoplexes in suppressing the development of lung metastases in nude mice. The development of A549 pulmonary metastases was inhibited significantly, and the numbers of metastatic tumor colonies found on the surfaces of lungs from mice inoculated with A549 cells were reduced by B60% in animals treated with p-shFE/lipoplexes compared with those in control treatment groups (Figures 5a and  b) . H&E staining also showed that lungs treated with p-shFE/ lipoplexes contained only a few small nodules; most of the lung was free of tumor. In contrast, metastasis nodules occupied most of the lung tissue from control groups (Figure 5c ).
Statistical analysis revealed no significant difference between the p-shHK/lipoplexes group and the untreated group (P40.05), Targeting FAK and EGFR for treatment of lung cancer C Li et al thereby suggesting that the injection of the control plasmids had no obvious side effect on tumor growth.
Knockdown of FAK and EGFR inhibits cell proliferation, angiogenesis and induced apoptosis in vivo
To determine the biological effects of treatment with FAK and EGFR shRNA, A549 subcutaneous tumors harvested from mice following therapy were subjected to imaging measurements for cell proliferation (PCNA), apoptosis (TUNEL) and MVD (CD31). Treatment with p-shFAK/lipoplexes or p-shEGFR/lipoplexes resulted in a modest decrease in MVD compared with the 5% GS control (Figure 6a ; Po0.05), but the greatest decrease in MVD was noted in the targeted FAK and EGFR groups (72.7% decrease; Po0.01). There was a 37.5 and 33.3% reduction in the mean number of PCNA-positive cells in p-shFAK/lipoplexes-treated and p-shEGFR/lipoplexes compared with the control (Figure 6c ; Po0.05), respectively. The p-shFE/lipoplexes treatment group produced the largest reduction in PCNA-positive cells (70.8%; Po0.01). We further performed in situ TUNEL assay to evaluate the influence of oncogene knockdown on apoptosis of tumor cells. We observed an elevated apoptosis rate in tumors of mice injected with p-shFE/lipoplexes compared with that of tumors from mice injected with control group and 5% glucose (Figure 6c ; Po0.001). Thus, inhibition of tumor xenograft growth by blocking the FAK and EGFR pathway might be due to inhibition of tumor proliferation, neovascularization as well as induction of tumor apoptosis.
Toxicity observation
The animal weight was measured twice in a week and there were no significant differences among the five groups. No gross abnormalities were noticed in p-shFAK/lipoplexes-or p-shEGFR/ lipoplexes-or p-shFE/lipoplexes-treated mice. In addition, there were no significant pathological alterations in the liver, lung, kidney, spleen or heart as revealed by H&E histological staining.
DISCUSSION
Despite intensive efforts in the treatment of patients with NSCLC, the 5-year relative survival rate has not improved substantially. 26 Clinical outcomes have reached a plateau with conventional methods. Based on advances in the knowledge of tumor biology and mechanisms of oncogenesis, multiple specific molecular targets for NSCLC treatment have been developed. 27 Therefore, To date, two approaches to RNAi have been explored: chemically or enzymatically synthesized siRNA and plasmid vector-mediated RNAi. Chemically or enzymatically synthesized siRNA is costly, easily contaminated by RNase and has a relatively short half-life. However, plasmid vector-mediated shRNA may express siRNA stably and has a lower immunogenicity in vivo.
28
Recent studies have also demonstrated the potential of simultaneous inhibition of two or three genes using a plasmidbased siRNA system. The advantage of using multicistronic constructs over single constructs is that a single plasmid molecule can produce multiple RNAi molecules specific to more than one target, thereby enhancing the RNAi effect and resulting in higher efficiency. 29, 30 In this study, we used plasmid-based RNAi to target FAK and/or EGFR genes, which are markedly Targeting FAK and EGFR for treatment of lung cancer C Li et al overexpressed in a wide variety of human cancers, including NSCLC cancer, singly and simultaneously. 31, 32 Our data indicated that knockdown of FAK and EGFR expression by RNAi quite effectively downregulated FAK and EGFR protein expression in the NSCLC cell line A549 (Figure 1) . Although there is a little variation in the degree of gene silencing among the constructs, all these gene-specific RNAi plasmids reduced FAK and EGFR expression substantially compared with mock-or p-shHK-transfected cells. Moreover, we found that knockdown of both FAK and EGFR expression cooperatively inhibited cell proliferation and induced cell apoptosis of A549 lung cancer cells.
To demonstrate whether the observed inhibitory effects of FAK and EGFR shRNAs on tumor cell growth in vitro could be reproduced in vivo, we evaluated the efficacy of FAK-EGFR shRNAs in suppressing tumor growth by injecting p-shFE vectors encapsulated in DOTAP-chol cationic liposome via tail vein into A549 tumor xenografts in nude mice. Growth of A549 tumor was suppressed significantly by treatments with p-shFE/lipoplexes. Furthermore, we explored the tumor-suppressing potential of FAK-EGFR shRNAs in inhibiting experimental metastases in vivo by systemic administration of p-shFE/lipolexes. The development of metastases was inhibited effectively by the p-shFE/lipolexesmediated transfer of the FAK-EGFR shRNAs. Similarly, this combination therapy yielded a higher incidence of apoptosis of tumor cells, resulting in lower values for MVD and PCNA staining positive cells compared with the other treatment groups. These in vivo data are consistent with the in vitro data, further supporting the roles of FAK-EGFR shRNAs in the treatment of NSCLC.
Gene therapy is a potential strategy for curing cancer and other diseases, but delivery of therapeutic genes to disseminated tumor sites has been a major challenge owing to the lack of an efficient vector delivery system. Although intravenous delivery of naked plasmids has been applied to block tumor growth in xenograft models owing to its benefits of safety and simplicity, the effect was limited probably due to the short half-life of the plasmids in vivo. At present, sufficient evidences have proved that cationic liposomes are the most extensively investigated non-viral vector and have been successfully used to deliver genes, proteins, oligonucleotides and antibiotics in several cell types. [33] [34] [35] Drugs encapsulated in cationic liposomes have the ability of transporting through large pores in the tumor vessel walls and are anticipated to be transported without rapid degradation, which generally do not exist in normal vessels and appear to be a result of the rapid angiogenesis occurring in tumors, they make the encapsulated drugs targetable and localize in tumor sites. 36, 37 In our lab, we used DOTAP-chol liposome as the vector deliver system and demonstrated that it gets the advantage of highly efficient in vitro and in vivo and is the most characterized system. [38] [39] [40] The choice of DOTAP-chol liposome mainly depended on several parameter, such as biodegradation, biodistribution and toxicity. 41 The validity of lipid-based gene delivery is also supported by previous studies using DOTAP-chol liposomes to deliver tumor suppressor genes and inhibit tumorigenicity. 42, 43 Furthermore, DOTAP:chol-FUS1 complex has entered Phase I clinical trials against advanced lung cancers. 44 To avoid the dose-dependent toxicity of DNA/cationic liposome complexes in vivo, we treated mice at a low dose (intravenous 5 mg DNA/25 mg liposome per mouse).To ensure the transfection efficacy, it was evaluated by injecting p-EGFP-N1/ DOTAP-cho liposome complexes intravenously in A549 xenografts model before the treatment. Our results indicated that a low dose of pDNA/lipoplexes can efficiently deliver pDNA to A549 lung tumor xenografts. Moreover, we did not find any side effects in animals by H&E histological staining.
In summary, our study shows that vector-based dual shRNA expression system can efficiently inhibit FAK and EGFR in vitro and systematic delivery of p-shFE by cationic liposomes resulted in reduction of FAK and EGFR expression, leading to decreased tumor vascularity, proliferation and increased apoptosis in vivo.
These results indicate that simultaneously targeting FAK and EGFR with shRNAs may have therapeutic benefit in the treatment of NSCLC.
